Fig. 4From: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosisCategorical changes in lung function before and after treatment. a Total cohort; b Advanced group; c Non-advanced group. Disease progression was defined as a ≥ 10% absolute decline in FVC over 12 months. Pre, pre-treatment; Post, post-treatmentBack to article page